Nora Isberner

518 total citations
14 papers, 140 citations indexed

About

Nora Isberner is a scholar working on Infectious Diseases, Genetics and Oncology. According to data from OpenAlex, Nora Isberner has authored 14 papers receiving a total of 140 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 5 papers in Genetics and 4 papers in Oncology. Recurrent topics in Nora Isberner's work include Chronic Lymphocytic Leukemia Research (4 papers), COVID-19 Clinical Research Studies (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Nora Isberner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), COVID-19 Clinical Research Studies (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Nora Isberner collaborates with scholars based in Germany, China and France. Nora Isberner's co-authors include Hartwig Klinker, Oliver Scherf‐Clavel, Max Kurlbaum, Theo Pelzer, Götz Ulrich Grigoleit, Sabrina Kraus, Charis Kalogirou, Maria-Elisabeth Goebeler, Bastian Schilling and Siegbert Rieg and has published in prestigious journals such as Analytical and Bioanalytical Chemistry, Cancers and Journal of Pharmaceutical and Biomedical Analysis.

In The Last Decade

Nora Isberner

13 papers receiving 139 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nora Isberner Germany 8 40 36 36 34 27 14 140
Sharmila Rajan United States 6 43 1.1× 69 1.9× 39 1.1× 13 0.4× 18 0.7× 11 179
Donald Brooks United States 7 50 1.3× 44 1.2× 53 1.5× 23 0.7× 28 1.0× 14 184
Sylvester Pawlak United States 8 61 1.5× 98 2.7× 26 0.7× 78 2.3× 6 0.2× 10 282
Muneo Aoyama Japan 8 40 1.0× 98 2.7× 51 1.4× 30 0.9× 12 0.4× 20 217
Е. А. Smolyarchuk Russia 8 37 0.9× 59 1.6× 39 1.1× 73 2.1× 4 0.1× 37 224
Hlíf Steingrímsdóttir Iceland 5 25 0.6× 31 0.9× 12 0.3× 25 0.7× 31 1.1× 10 101
Michael Weigand Germany 5 30 0.8× 64 1.8× 64 1.8× 53 1.6× 8 0.3× 8 238
Valentina Isgrò Italy 7 79 2.0× 20 0.6× 76 2.1× 45 1.3× 8 0.3× 16 215
Sujata Sharma India 10 26 0.7× 79 2.2× 46 1.3× 23 0.7× 9 0.3× 24 224
Amy Wang United States 8 17 0.4× 111 3.1× 11 0.3× 26 0.8× 22 0.8× 14 239

Countries citing papers authored by Nora Isberner

Since Specialization
Citations

This map shows the geographic impact of Nora Isberner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nora Isberner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nora Isberner more than expected).

Fields of papers citing papers by Nora Isberner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nora Isberner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nora Isberner. The network helps show where Nora Isberner may publish in the future.

Co-authorship network of co-authors of Nora Isberner

This figure shows the co-authorship network connecting the top 25 collaborators of Nora Isberner. A scholar is included among the top collaborators of Nora Isberner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nora Isberner. Nora Isberner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Kraus, Sabrina, Götz Ulrich Grigoleit, Anja Gesierich, et al.. (2023). Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib. Journal of Pharmaceutical and Biomedical Analysis. 228. 115311–115311. 10 indexed citations
2.
Schilling, Bastian, Sabrina Kraus, Götz Ulrich Grigoleit, et al.. (2022). Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio. Journal of Pharmaceutical and Biomedical Analysis. 211. 114623–114623. 23 indexed citations
3.
Isberner, Nora, Anja Gesierich, Bastian Schilling, et al.. (2022). Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma. Cancers. 14(19). 4566–4566. 5 indexed citations
4.
Hanses, Frank, Melanie Stecher, Michael Dreher, et al.. (2022). COVID‐19 mortality in cirrhosis is determined by cirrhosis‐associated comorbidities and extrahepatic organ failure: Results from the multinational LEOSS registry. United European Gastroenterology Journal. 10(4). 409–424. 8 indexed citations
5.
6.
Kraus, Sabrina, Götz Ulrich Grigoleit, Max Kurlbaum, et al.. (2022). A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients. Pharmaceutics. 14(12). 2556–2556. 8 indexed citations
7.
Pilgram, Lisa, Lukas Eberwein, Kai Wille, et al.. (2021). Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. Infection. 49(4). 725–737. 12 indexed citations
8.
Isberner, Nora, Sabrina Kraus, Götz Ulrich Grigoleit, et al.. (2021). Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial. Cancer Chemotherapy and Pharmacology. 88(6). 973–983. 10 indexed citations
9.
Bai, Tao, Xue Zhu, Xiang Zhou, et al.. (2021). Reliable and Interpretable Mortality Prediction With Strong Foresight in COVID-19 Patients: An International Study From China and Germany. Frontiers in Artificial Intelligence. 4. 672050–672050. 4 indexed citations
10.
Borgmann, Stefan, Karlheinz Seidl, Melanie Stecher, et al.. (2021). Specific Risk Factors for Fatal Outcome in Critically Ill COVID-19 Patients: Results from a European Multicenter Study. Journal of Clinical Medicine. 10(17). 3855–3855. 12 indexed citations
11.
Tometten, Lukas, Stefan Borgmann, Jochen Schneider, et al.. (2020). COVID-19 in cancer patients: Clinical characteristics and outcome - a first analysis of the LEOSS registry. Kölner Universitäts PublikationsServer (Universität zu Köln).
12.
13.
Isberner, Nora, et al.. (2020). Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. Journal of Chromatography B. 1159. 122399–122399. 6 indexed citations
14.
Isberner, Nora, et al.. (2020). Determination of Letermovir Serum Levels Can Be Useful in High-Risk Clinical Settings. Journal of the Pediatric Infectious Diseases Society. 9(3). 402–403. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sharmila Rajan Breakdown of academic impact, for papers by Donald Brooks Breakdown of academic impact, for papers by Sylvester Pawlak Breakdown of academic impact, for papers by Muneo Aoyama Breakdown of academic impact, for papers by Е. А. Smolyarchuk Breakdown of academic impact, for papers by Hlíf Steingrímsdóttir Breakdown of academic impact, for papers by Michael Weigand Breakdown of academic impact, for papers by Valentina Isgrò Breakdown of academic impact, for papers by Sujata Sharma Breakdown of academic impact, for papers by Amy Wang
Rankless by CCL
2026